Case report reveals unexpected stability of HER2-positive breast ductal carcinoma with microinvasion under targeted therapy, suggesting monitoring is essential.
Background Numerous studies have reported considerable heterogeneity in breast ductal carcinoma in situ with microinvasion (DCIS-MI) regarding clinical presentation, progression potential, and treatment strategies. Case presentation In this work, we report a case of rapidly progressing multiple metastases in a patient with DCIS-MI following conventional treatment. Subsequent fluorescence in situ hybridization (FISH) testing revealed HER2 gene overexpression. After receiving 10 cycles of trastuzumab-targeted therapy, the patient achieved a favorable prognosis and remains stable to date. Conclusion This case suggests that even patients with microinvasive lesions who are HER2-positive may exhibit unexpected stability under targeted therapy, warranting close surveillance in such cases.
No takes yet. Share an insight, caveat, or question.
Ruan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: